 |
|
|
| |
Map of GDF Countries Updated: 8 June 2006
GDF is ISO 9001:2000 compliant for provision of
quality-assured anti-TB drugs and related services to
eligible national TB control programmes.
|
|
|
 |
 |
|
Welcome to the Global Drug Facility
|
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to facilitate global DOTS expansion or maintenance to support the Stop TB Strategy.
PLANNED TENDERS IN '08 AND '09 FOR SUPPLY OF
FIRST- AND SECOND-LINE ANTI-TUBERCULOSIS DRUGS
INVITATIONS FOR SUBMISSION OF EXPRESSIONS OF INTEREST LAUNCHED ON 18 SEPTEMBER 2008
DEADLINES FOR SUBMISSION: 05 NOVEMBER 2008 (FIRST-LINE DRUGS) AND 30 NOVEMBER 2008 (SECOND-LINE DRUGS)
19 September, 2008
In an effort to facilitate access to high-quality affordable anti-tuberculosis drugs for countries with a high burden of tuberculosis (TB), the Global Drug Facility (GDF), the procurement arm of the Stop TB partnership, is inviting qualified anti-tuberculosis drug manufacturers of anti-tuberculosis drugs to submit expressions of interest (EoIs) to GDF. GDF supports implementation of the Stop TB Strategy in accordance with the Global Plan to stop TB (2006 - 2015), supplemented by the Global MDR/XDR TB Response Plan (2007-2008).
For more information and to access the invitations for EoI please CLICK HERE.
Results of the Tender for Desk Auditing Agencies for the Global Drug Facility (RFP Number 4951)
3 September, 2008
The GDF wishes to announce the result of its competitive Request for Proposals RFP Number 4951 designed to select an Agency or Agencies to undertake independent Desk Audit assessments of mission reports from annual visits to GDF grant recipients and/or direct procurement clients.
- In total 5 Responsive Proposals were received and adjudicated: 17 - 18 August
- Proposers were invited to witness the opening of Proposals and recording of financial offers and one Proposer attended.
- The technical scores for the Proposals ranged from: 100 to 380 points (out of maximum of 480 points)
- The financial offers ranged from: US$1693.60 to US$8229
- Two agencies were selected for contract awards on the basis of their technical scores and financial offers: Swiss Center for International Health, Swiss Tropical Institute (SCIH) (Primary awardee: 65% of annual number of audits) and German Leprosy and TB Relief Association (GLRA) (Secondary Awardee: 35% of annual number of audits).
GDF would like to congratulate SCIH and GLRA for their success and thank all Proposers for the efforts they made to prepare their Proposals and participate in this competition.
For further information please contact Maria Patyna at: patynam@who.int
New Long-Term Agreements (LTAs) with first-line TB drug suppliers and improved pricing system
19 February, 2008
From September through December 2007 the Global Drug Facility (GDF) conducted a competitive selection process among pre-qualified first-line drug manufacturers through its Procurement Agent, GTZ.
This competitive process is now complete, and GDF and GTZ are pleased to announce that awards have been made to five suppliers. Four of them - Svizera, Cadila, Strides and Lupin - were already serving as GDF suppliers. One new supplier, Macleods, also was selected. This expansion in the supplier pool indicates strong interest and competition among manufacturers, and augurs well for favourable pricing and availability of high quality anti-TB drugs.
GDF and GTZ have also introduced a new pricing system for first-line drugs that provides firmer estimates of total costs. Through consultation and cooperation with its agents, GDF is now able to list prices inclusive of quality assurance (QA) and Procurement Agent (PA) costs - a move that will aid clients in their budgeting and planning and lead to a more efficient drug procurement process.
GDF is committed to providing affordable high-quality anti-tuberculosis (TB) drugs to countries with a high TB burden and stimulating capacity and competition in the production sector.
STOP TB PARTNERSHIP AND UNITAID JOIN FORCES TO ADDRESS ANTI-TUBERCULOSIS DRUG SHORTFALLS
8 October 2007
Geneva -- The Stop TB Partnership's Global Drug Facility and UNITAID today announced a collaboration with 19 countries to address life-threatening shortages of anti-tuberculosis (TB) drugs. The initiative will provide these drugs to countries that are scaling up their TB control efforts and have confirmed future support from the Global Fund to Fight AIDS, Tuberculosis and Malaria or another donor but are not able to cover their full needs at present.
"This collaboration will deliver drugs to more than three-quarters of a million people who otherwise might not get treatment or could have their treatment interrupted because no drugs were available," said Dr Marcos Espinal, Executive Secretary of the Stop TB Partnership. "Getting anti-TB drugs to people who need them and making sure they complete their treatment is the best weapon we have for preventing drug-resistant TB."
The project, which is restricted to anti-TB treatments suitable for people whose form of TB is not resistant to standard therapies, also provides for the establishment of a stockpile of anti-TB drugs that will be made available to countries facing shortages because of humanitarian emergencies or inadequate capacity for planning orders.
Press release
Global Drug Facility delivers tuberculosis treatments for 10 million people in six years
29 May, 2007
The Stop TB Partnership announced today that its drug supply arm, the Global Drug Facility, has provided anti-TB drug treatments for 10 million people to 78 countries in the past six years. A reliable supply of drugs is crucial both for preventing deaths from this often lethal disease and for fighting the spread of drug-resistant TB. Click here to read more.
Statements of support for GDF 
GDF Achievements Report: 10 Million Treatments Supplied in 6 Years
|
|
|
